Informações de Alkermes Plc

Mais detalhes de Alkermes Plc Empresa

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.



Código da empresaALKS

Nome da EmpresaAlkermes Plc

Data de listagemJul 16, 1991

CEOMr. Richard F. Pops

Número de funcionários1800

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 16

EndereçoConnaught House

CidadeDUBLIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísIreland

Código postalD04 C5Y6

Telefone35317728000

Sitehttps://www.alkermes.com/

Código da empresaALKS

Data de listagemJul 16, 1991

CEOMr. Richard F. Pops

Executivos da empresa Alkermes Plc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

Outro

21.09M

5.40%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

Outro

21.09M

5.40%

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

Outro

59.83%

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

Outro

59.83%

Tipos de investidores

Investidores

Proporção

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

14.45%

Research Firm

3.16%

Pension Fund

2.38%

Individual Investor

1.65%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

743

174.30M

105.56%

-28.06M

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

23.73M

14.37%

-251.67K

-1.05%

Jun 30, 2025

The Vanguard Group, Inc.

18.45M

11.18%

+290.40K

+1.60%

Jun 30, 2025

T. Rowe Price Associates, Inc.

9.86M

5.97%

-1.76M

-15.13%

Jun 30, 2025

State Street Investment Management (US)

8.21M

4.97%

+185.59K

+2.31%

Jun 30, 2025

Baker Bros. Advisors LP

6.41M

3.88%

+1.93M

+42.99%

Jun 30, 2025

Renaissance Technologies LLC

5.81M

3.52%

+71.33K

+1.24%

Jun 30, 2025

RTW Investments L.P.

4.68M

2.84%

-2.20M

-31.99%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.02M

2.44%

+83.86K

+2.13%

Jun 30, 2025

American Century Investment Management, Inc.

3.66M

2.22%

+191.55K

+5.53%

Jun 30, 2025

JP Morgan Asset Management

3.95M

2.39%

-179.85K

-4.36%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

AdvisorShares Psychedelics ETF

5.6%

iShares Neuroscience and Healthcare ETF

4.16%

Invesco S&P SmallCap Health Care ETF

3.15%

First Trust NYSE Arca Biotechnology Index Fund

3.08%

ALPS Medical Breakthroughs ETF

2.88%

Knowledge Leaders Developed World ETF

1.7%

Abacus FCF International Leaders ETF

1.46%

Langar Global HealthTech ETF

1.46%

SPDR S&P Biotech ETF

1.39%

Invesco S&P SmallCap Quality ETF

1.33%

Ver Mais

AdvisorShares Psychedelics ETF

Proporção5.6%

iShares Neuroscience and Healthcare ETF

Proporção4.16%

Invesco S&P SmallCap Health Care ETF

Proporção3.15%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.08%

ALPS Medical Breakthroughs ETF

Proporção2.88%

Knowledge Leaders Developed World ETF

Proporção1.7%

Abacus FCF International Leaders ETF

Proporção1.46%

Langar Global HealthTech ETF

Proporção1.46%

SPDR S&P Biotech ETF

Proporção1.39%

Invesco S&P SmallCap Quality ETF

Proporção1.33%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados